Cognizant stock falls 3.9% with no clear new catalyst

Cognizant shares are indicated at $58.51, down 3.9% today. The company’s latest disclosed quarterly results were released July 29, and the documents reviewed provide no October 5 company announcement explaining the decline. The cause is therefore unclear. A price move is observable; its explanation is not.

The recent headlines supplied include a report that third-quarter results are scheduled before the market opens October 29. That is a future reporting date, not a newly disclosed operating setback. The next scheduled results could provide fresh evidence, but they cannot explain today’s trading on their own.

Cognizant’s latest disclosed results came on July 29, 2026: second-quarter revenue rose 4.5% year over year to $5.481 billion, while bookings fell 6% in the quarter. (Cognizant Q2 2026 earnings release) GAAP operating margin was 15.9%, up from 15.6%, and GAAP diluted EPS increased to $1.36 from $1.31. That is steady execution, not a sudden acceleration.

The segment mix explains the more complicated picture. Financial Services, which accounted for 31.6% of Q2 revenue, grew 12.0%; Health Sciences, at 28.7% of revenue, grew 1.4%. Products and Resources and Communications, Media and Technology each grew around 1% to 2%. A strong banking and financial-services quarter is carrying much of the visible momentum, while the rest of the portfolio is moving at a slower pace. (Cognizant Q2 2026 earnings release)

The demand evidence is mixed in another way. Trailing-12-month bookings rose 5% to $29.1 billion, but quarterly bookings fell 6%. Bookings measure contract value, not near-term recognized revenue; Cognizant says timing and client spending affect conversion, and most contracts can be ended on short notice. The annual figure is encouraging, but the quarterly decline deserves attention.

For full-year 2026, management forecast constant-currency revenue growth of 4.0% to 5.5% and adjusted diluted EPS of $5.70 to $5.82; it raised the EPS outlook while leaving adjusted margin guidance at 16.0% to 16.2%. (Cognizant Q2 2026 earnings release) These are forecasts, not results, and adjusted measures exclude specified items. The release also reports $84 million of Q2 Project Leap charges and an $81 million benefit tied to India contribution obligations, a reminder that headline EPS and underlying operating progress do not always line up neatly.

For investors, the release supports a durable-services-business argument, with solid cash generation and low valuation multiples, but it does not yet prove broad-based demand recovery. The AI strategy could expand work in data modernization and implementation; the harder test is whether these offerings translate into sustained organic growth and bookings, beyond acquisitions and third-party product sales.

At $58.51, CTSH trades at 12.7 times trailing EPS and has an indicated trailing free-cash-flow yield of 8.9%. A preliminary, direct-equity valuation applies an assumed 12 times the $2.5 billion trailing FCF, producing $30.0 billion of equity value; divided by 477 million diluted shares, that is $62.89 per share. This simple multiple is a valuation assumption, not company guidance, and does not capture changes in growth or margins.

The roughly 7% implied premium to the current price is too small to label the shares undervalued under our valuation thresholds. The conclusion is fairly valued, with moderate risk: the balance sheet has historically carried net cash, but the Astreya acquisition and borrowing, uneven segment growth, and client spending sensitivity complicate the near-term picture. Cognizant reported $1.0 billion borrowed under its revolving facility for the acquisition; it also repurchased shares aggressively, so capital allocation and the resulting debt position merit scrutiny.

The next useful evidence is the October 29 Q3 report: whether Financial Services remains strong, whether weaker segments improve, and whether bookings recover from Q2’s decline. If reported revenue growth broadens and bookings strengthen without margin erosion, the case for a higher multiple improves. If growth remains concentrated and bookings keep slipping, the low earnings multiple may be a rational discount, not a market mistake.